Viatim is commonly used for active immunisation to help with typhoid fever and Hepatitis A virus infection. This makes it a relevant element of prophylactic care in contexts involving heightened systemic burden. The vaccine is considered relevant for individuals from 16 years of age.

Viatim may assist with managing symptoms related to systemic imbalance, including those linked to high fevers, gastrointestinal discomfort, and acute liver inflammation. It is applied across domains where additional symptomatic support is needed. This combined vaccine is commonly used in clinical settings that involve acute or unstable symptom patterns, and is considered relevant for international travellers to areas where both pathogens are endemic. “The combined approach is commonly used to help with protection against typhoid fever and Hepatitis A virus infection, supports the patient during difficult episodes by easing distress.”

Quick Fact: Support for Systemic Discomfort Viatim helps improve day-to-day comfort during symptomatic periods and assists with maintaining functional stability when conditions present with systemic or localized discomfort.

Regulatory References

1. SUMMARY OF PRODUCT CHARACTERISTICS

Who Can and Cannot Use Viatim? — Official Regulatory Information

This section outlines the specific population eligibility criteria for Viatim, strictly based on government-approved regulatory documents.

Eligibility Classifications (High-Level)

Resulting Eligibility Structure

Official eligibility statements:

• Viatim is explicitly indicated for use in subjects from 16 years of age.
• The vaccine is contraindicated if there is known hypersensitivity to the active substances or any residual component.
• Administration must be postponed in the case of acute severe febrile illness.

Connection to the overall eligibility profile (2–4 sentences): Official regulatory documents define Viatim's eligibility through strict parameters, primarily limiting standard use to individuals aged 16 years and older. Non-eligibility is established by absolute contraindications like acute illness, while certain groups, such as immunosuppressed individuals or pregnant women, fall under a classified restricted use status.

Viatim Interactions with other medicines and products

The official regulatory profile for Viatim, a biological medicinal product for active immunisation, defines its interactions based primarily on the potential for other substances or conditions to affect the expected immune response, rather than on small-molecule metabolism.

Pharmacodynamic Interaction with Immunosuppressive Agents

The core documented interaction involves the medicinal product category of Immunosuppressive Agents. This category includes high-dose systemic corticosteroids, cytotoxic drugs, and other therapies that suppress host immunity. Co-administration with these agents is officially documented to interfere with the expected active immune response. This pharmacodynamic interaction can lead to a diminished protective effect, potentially resulting in inadequate seroprotection against both Hepatitis A and Typhoid Fever. This documented outcome is classified as a clinically significant interaction due to the potential loss of protective immunity. Regulatory documentation also notes that the protective immune response may be similarly diminished in immunocompromised individuals due to their underlying health status. No specific individual drug names are universally listed in this classification, as the interaction relies on the drug category's effect on the host.

Procedural Constraint for Concomitant Vaccines

A specific procedural constraint exists when Viatim is administered simultaneously with other vaccines. Regulatory documentation requires that if co-administration occurs, a separate anatomical injection site must be utilized for each distinct vaccine product. No other specific interactions with food, alcohol, herbal products, or supplements are explicitly documented.

Viatim exerts its pharmacodynamic effects by acting as an agonist for the Vitamin D Receptor (VDR). The active metabolite binds to the VDR, forming a complex that heterodimerizes with the Retinoid X Receptor (RXR). This VDR/ RXR complex translocates to the cell nucleus, where it binds to specific Vitamin D Response Elements (VDREs) on target DNA, thereby modulating the transcription of numerous genes. This genomic signaling cascade primarily regulates the synthesis of proteins involved in mineral transport. Specifically, this mechanism enhances the capacity of the intestine and kidneys to absorb and reabsorb calcium and phosphate, respectively. The resulting increase in circulating mineral levels contributes to the mineralization of the bone matrix and the modulation of systemic physiological equilibrium. Furthermore, Viatim engages VDRs present in various immune cells and skin cells, influencing cytokine expression and cell differentiation pathways.

Official Administration Guidelines for Viatim

Viatim is administered as a single dose by intramuscular injection, routinely into the deltoid muscle. It is indicated for individuals 16 years of age and older.

Administration Scope

Preparation and Procedural Steps

Prior to injection, the vaccine must be stored between +2 and +8 C and must be discarded if it has been frozen. The syringe's contents should be shaken well and visually inspected for any particulate matter or abnormal appearance before administration.

For a co-administration with other injections, all injections must be given at separate sites, preferably in a different limb. If multiple injections are given in the same limb, they must be separated by at least 2.5 cm. In the event of a missed dose for periodic re-vaccination, consult the prescribing information for guidance on resuming the appropriate schedule.

The official guidelines establish Viatim as a parenteral vaccine with a clear single-dose regimen and strict handling and administration protocols. These instructions define the specific intramuscular route and preparation requirements, such as shaking and inspection, to ensure the product is administered correctly and safely.

Research Evidence / Overview of Studies for Viatim

Evidence for Simultaneous Active Immunisation against Hepatitis A and Typhoid Fever

The primary research for Viatim has been conducted in the form of Randomized Controlled Trials (RCTs) and supporting observational settings. These studies examined the immune system's measurable reaction when the components for Hepatitis A and Typhoid Fever are administered together. These trials were not used in research exploring how symptoms change over time, but rather applied in studies evaluating the generation of specific antibodies (serological markers) in the blood.

In these studies, researchers monitored primarily by measuring two main outcomes: the concentration of Hepatitis A antibodies (anti-HAV) and the concentration of Typhoid antibodies (anti-Vi) in the blood. These antibody levels are used as serological markers and are evaluated as the primary outcomes in these studies. Findings describe patterns observed in the studies where the antibody concentrations were reported following the administration of the vaccine. Study designs often included comparisons to recipients of separate, individual vaccines.

While these trials provide findings that contribute to understanding antibody patterns in the short term, the certainty of evidence remains lower regarding the direct, long-term clinical outcome of preventing actual infection. The results apply primarily to the populations studied, mainly healthy adults aged 16 and older.

Research on Viatim's Role in Vaccination Schedules (Interchangeability)

Viatim was also evaluated in comparative research exploring the short-term changes in serological markers when it is used as the first dose, followed by a different, licensed monovalent Hepatitis A vaccine as a booster at a later time. Studies explored the use of these products in an interchangeable sequence. The research describes patterns observed in the Hepatitis A antibody concentrations after the booster dose was given, comparing the resulting antibody concentrations to standard two-dose schedules using a single vaccine brand.

Crucially, these studies provided very limited documentation on the persistence of anti-Vi antibody levels for the Typhoid component when Viatim is used in this specific sequential manner. Follow-up durations were limited in this area of research, meaning research provides context but not individual predictions for the long-term status of this interchangeability.

Tracking Persistence: Long-term Follow-up and Antibody Durability

Studies explored the persistence of antibody levels over defined time intervals, with follow-up durations typically limited to a few years. The research describes patterns observed in how antibody levels change over the intermediate term, including reported observations of decreasing anti-Vi antibody levels over the intermediate follow-up periods. Long-term data are not fully established regarding the sustained reduction in infection risk over many years.

Research is ongoing, but currently, data comparing various sequential scenarios is limited, and information for certain subgroups (including those with functional limitations or comorbidities) remains insufficient.

Key Studies & References

1. ViATIM suspension and solvent for suspension for injection, pre-filled syringe - Summary of Product Characteristics (SmPC)

Common questions about Viatim (FAQ)

Q: Are the side effects of Viatim usually severe?

A: Regulatory documents indicate that the most common side effects are mild or moderate local reactions, such as pain or swelling at the injection site, and general symptoms like headache or fatigue. These symptoms are typically transient and resolve within one to two days. Rare, severe allergic reactions, such as anaphylaxis, are part of the documented safety profile but are listed with a frequency of 'Not known' in official product information.

Q: Can Viatim cause changes in appetite or weight?

A: The official product safety information does not list changes in appetite or changes in body weight as very common, common, or uncommon documented side effects for Viatim.

Q: Can Viatim affect sleep patterns?

A: While specific changes to sleep patterns are not explicitly listed, the documentation confirms certain systemic effects, such as headache and fatigue, that can occur.

Q: Is Viatim available in different strengths?

A: Viatim is officially presented as a single, standardized dose (1 mL) for injection. Regulatory documents do not list or define alternative strengths for the active ingredients.

Q: Can Viatim cause dizziness or affect driving?

A: Official safety information lists dizziness as an uncommon side effect. Safety information regarding products that can cause dizziness notes that an individual's ability to drive or operate machinery may be impaired.

Q: Can Viatim be crushed or split?

A: Viatim is a combination of a suspension and a solution packaged in a pre-filled syringe intended for intramuscular injection. Due to its pharmaceutical form and route of administration, this product cannot be physically manipulated by crushing or splitting.

Q: Is it normal for Viatim to cause a metallic taste?

A: A metallic taste is not listed in the officially documented adverse reactions that are classified as very common, common, or uncommon for Viatim.

Q: Do clinical trials for Viatim include diverse populations?

A: Studies used for the vaccine's approval were primarily conducted in healthy adults aged 16 years and older. Regulatory documents indicate that data regarding the use and effect of Viatim in certain specific subgroups (such as those with underlying health conditions) remains limited.

Q: Is Viatim available in the United Kingdom?

A: Regulatory documents from the UK's health authorities (MHRA) confirm that Viatim is licensed for use and classified as a Prescription Only Medicine (POM) in the United Kingdom.

Q: What is the official classification of Viatim (e.g., controlled substance, prescription only)?

A: Viatim is legally classified as a Prescription Only Medicine (POM) in regulatory documentation. As a biological medicinal product, it is not classified as a controlled substance.

Q: Is Viatim known to cause drug dependence or addiction?

A: As a vaccine and biological medicinal product, the official safety profile for Viatim does not contain any warnings or reports related to drug dependence, misuse, or addiction.

Q: Do official documents mention any mental health side effects associated with Viatim?

A: The official adverse reactions list includes Nervous System Disorders, such as headache and dizziness. However, no specific psychiatric or mental health side effects, such as depression or anxiety, are listed among the documented very common, common, or uncommon reactions.

Q: How quickly do people generally expect Viatim to start working?

A: The intended effect of Viatim is to establish a protective immune response called seroprotection. Regulatory documents indicate that protective levels of antibodies may not be fully reached until approximately 14 days after the vaccine is administered, which is the required period before potential exposure.

Q: What types of foods should be avoided when taking Viatim?

A: Official regulatory documents explicitly state that there are no specific documented interactions between Viatim and foods, alcohol, or herbal supplements.

Q: Is it safe to drink alcohol while taking Viatim?

A: Regulatory documentation explicitly states that there are no specific documented interactions between Viatim and alcohol. The main documented interactions relate to other vaccines and immunosuppressive agents.

Q: Does Viatim interact with common over-the-counter pain relievers?

A: Official regulatory documents list interactions primarily with immunosuppressive agents and co-administered vaccines. No specific interactions with common over-the-counter pain relievers are officially documented for Viatim.

Q: Does Viatim interact with any herbal supplements?

A: Regulatory documentation explicitly states that there are no specific documented interactions between Viatim and herbal supplements. The primary focus of documented interactions is on substances that might interfere with the intended immune response.

Q: Can Viatim be taken with blood pressure medication?

A: Regulatory documentation for Viatim lists interactions mainly with other vaccines and immunosuppressive agents. No specific negative interactions with blood pressure medications are officially documented.

Q: What if I have an allergic reaction to Viatim?

A: Known hypersensitivity to Viatim's components is listed as an absolute contraindication, and severe allergic reactions (anaphylactic shock) are documented as a potential, though rare, adverse event. Regulatory documents note that if an allergic reaction is suspected, immediate professional medical assistance is warranted.

Q: What happens when someone stops taking Viatim?

A: Viatim is a vaccine providing active immunity for a defined duration. Failure to receive the recommended booster dose for the typhoid component is associated with a documented decline in antibody levels, indicating a potential loss of protection over time.

Q: What is the duration of action for Viatim in the body?

A: The duration of protection is linked to the requirement for revaccination against typhoid fever every three years. Studies indicate that the Hepatitis A component's antibodies have been shown to persist for many years following the full course.

Q: What distinguishes Viatim's mechanism from similar drugs, as described in official documents?

A: Viatim is officially distinguished as a combination vaccine that provides simultaneous active immunisation against both Hepatitis A and Typhoid Fever. Its unique pharmaceutical form involves a dual-chamber pre-filled syringe, designed to keep its two active components separate until the time of injection.

Q: Why is Viatim sometimes prescribed alongside other medications?

A: Regulatory documents provide context for co-administration with other injectable vaccines, stating that if Viatim is given simultaneously, a separate anatomical injection site is required for each product. Studies have examined this co-administration to determine if the expected immune response remains effective.

Q: Why are there warnings about grapefruit with some medicines, and does this apply to Viatim?

A: Warnings about grapefruit relate to its ability to interfere with how the liver processes certain medications. Viatim is a vaccine, and its regulatory documentation explicitly states that no specific interactions with food, including grapefruit, are documented.

Q: What are the signs that Viatim is working for its intended use?

A: Viatim's intended purpose is to achieve seroprotection (protective immunity). This effect is confirmed by laboratory measurements that show the generation of specific antibody levels in the blood, which are the serological markers evaluated in official studies.

How to Store and Dispose of Viatim?

The storage and disposal of Viatim, a combination vaccine, must strictly follow regulatory requirements to maintain the integrity of its active components.

Storage Conditions

Handling and Disposal

The medicine must be kept out of the sight and reach of children.

Any unused or expired Viatim must be disposed of according to local requirements for medicinal products and not via wastewater or household waste. Used syringes and needles must be placed immediately into a sharps container.